Treatment of Disseminated Intravascular Coagulation and Its Prodromal Stage with Gabaxate Mesilate (FOY): A Multi-Center Trial
| العنوان: | Treatment of Disseminated Intravascular Coagulation and Its Prodromal Stage with Gabaxate Mesilate (FOY): A Multi-Center Trial |
|---|---|
| المؤلفون: | Masaru Miyake, Kiyoshi Takatsuki, sup> Tsuda, Shouzo Chiba, Mitsuo Kotsuru, Kazunor j, Takashi Okamura, Kenzo Tanaka, Takashi Itoga, Michihito Ichimaru, Hidehiko Saito, Kouhei Hara, Yoshiyuki Niho, Akihiro Igata |
| المصدر: | Acta Haematologica. 90:120-124 |
| بيانات النشر: | S. Karger AG, 1993. |
| سنة النشر: | 1993 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Adolescent, Gabexate, medicine.drug_class, medicine.medical_treatment, Gastroenterology, hemic and lymphatic diseases, Internal medicine, medicine, Coagulopathy, Humans, Infusions, Intravenous, Aged, Aged, 80 and over, Disseminated intravascular coagulation, Chemotherapy, Heparin, business.industry, Prodromal Stage, Anticoagulant, Hematology, General Medicine, Disseminated Intravascular Coagulation, Middle Aged, medicine.disease, Surgery, Clinical trial, Treatment Outcome, Drug Therapy, Combination, Female, business |
| الوصف: | One hundred and ninety-one patients with disseminated intravascular coagulation syndrome (DIC) or its prodromal stage (preDIC) were treated with only gabaxate mesilate (FOY) (group G) or a combination of gabaxate and unfractionated heparin (group GH), and the efficacy of gabaxate was evaluated in a multicenter study. Following the treatment, the mean DIC score, which was evaluated on the basis of clinical symptoms and hemostatic parameters, decreased significantly to 5.58 +/- 3.48 from 6.75 +/- 3.14 in group G (p0.001) and to 6.34 +/- 3.33 from 7.31 +/- 3.00 in group GH (p0.05). In patients with overt DIC, the mean score decreased to 6.71 +/- 3.54 from 8.42 +/- 2.84 (p0.001). In DIC, the rate of overall efficacy was 46.2% in group G and 35.1% in group GH. In preDIC, it was 41.5% in group G and 27.3% in group GH. No side effects, including severe bleeding, were found in this study. The results indicate that gabaxate mesilate is clinically effective for patients with DIC and preDIC. |
| تدمد: | 1421-9662 0001-5792 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40d0df12e62f483746faf67f9f0d16d0 https://doi.org/10.1159/000204391 |
| رقم الأكسشن: | edsair.doi.dedup.....40d0df12e62f483746faf67f9f0d16d0 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14219662 00015792 |
|---|